Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

NCT03187769 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

426

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizophreniform Disorders
Bipolar I Disorder

Interventions

DRUG: ALKS 3831
DRUG: Olanzapine

Sponsor

Alkermes, Inc.